CPAI - ETF AI Analysis

Top Page

Counterpoint Quantitative Equity ETF (CPAI)

Rating:60Neutral

Price Target:―

CPAI, the Counterpoint Quantitative Equity ETF, has a solid but not outstanding overall rating, helped by strong contributors like Newmont Mining and Micron, which show robust financial performance, growth prospects, and generally supportive technical trends. However, holdings such as AMN Healthcare Services and Solid Power, which face financial pressures and mixed or bearish technical signals, weigh on the fund’s appeal. The main risk factor is that several holdings struggle with profitability, cash flow, or leverage, which can add volatility and limit upside if their turnarounds are slow.

Positive Factors

Strong Recent Performance

The ETF has shown strong gains over the past year-to-date and recent months, indicating positive momentum.

Top Holdings with Solid Gains

Many of the largest positions, including companies in energy, technology, and specialty materials, have delivered strong year-to-date performance that supports the fund’s returns.

Broad Sector Diversification

Holdings spread across health care, technology, industrials, materials, consumer sectors, financials, energy, and communications help reduce the impact of weakness in any single industry.

Negative Factors

High Expense Ratio

The fund’s relatively high fee means more of the investment return goes to costs instead of staying in investors’ pockets.

Heavy U.S. Concentration

With the vast majority of assets in U.S. stocks and only a small slice abroad, investors get limited geographic diversification.

Smaller Asset Base

The fund’s modest size may lead to lower trading volume and potentially wider bid-ask spreads compared with larger, more established ETFs.

CPAI vs. SPDR S&P 500 ETF (SPY)

AUM189.37M

RegionNorth America

Expense Ratio0.75%

Beta1.06

IssuerCounterpoint

Inception DateNov 28, 2023

Dividend Yield0.82%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume31,229

30 Day Avg. Volume33,385

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

54.35

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering50

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

CPAI Summary

The Counterpoint Quantitative Equity ETF (CPAI) is an actively managed fund that aims to cover almost the entire U.S. stock market, using a data-driven approach instead of tracking a set index. It mixes different sizes and styles of companies, from growth to value, across many sectors like health care, technology, and industrials. Well-known holdings include Micron and Herbalife. Someone might invest in CPAI to get broad diversification and long-term growth potential in a single fund. A key risk is that it still moves with the overall stock market, so its value can go up and down significantly.

How much will it cost me?The Counterpoint Quantitative Equity ETF (CPAI) has an expense ratio of 0.75%, meaning you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, using a quantitative approach to select stocks rather than simply tracking an index.

What would affect this ETF?The Counterpoint Quantitative Equity ETF (CPAI), with its focus on the U.S. market and diverse sector exposure, could benefit from strong growth in technology and healthcare sectors, driven by innovation and increased demand. However, it may face challenges from rising interest rates or economic slowdowns, which could negatively impact consumer spending and cyclical industries. Regulatory changes or geopolitical tensions affecting North America could also influence the ETF's performance.

CPAI Top 10 Holdings

This U.S.-focused quant fund is leaning into a mix of niche growth stories and cyclical rebound plays rather than the usual mega-cap tech. Micron is the clear engine here, riding strong AI and memory demand, while Eos Energy and CompoSecure add extra spark with rising momentum despite lingering financial worries. Herbalife has been surprisingly lively too, helping performance rather than hurting it. On the flip side, Solid Power and AMN Healthcare look more like dead weight for now, with choppy trends that can tug on returns. Sector-wise, it’s a broad spread across health care, tech, industrials, and materials, so no single theme completely dominates the wheel.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
BKD	Brookdale Senior Living	2.84%	$5.46M	$3.95B	204.41%	61 Neutral
MU	Micron	2.64%	$5.08M	$449.96B	303.36%	79 Outperform
AAP	Advance Auto Parts	2.63%	$5.05M	$3.41B	26.20%	48 Neutral
Q	Qnity Electronics, Inc.	2.58%	$4.97M	$23.45B	―	―
ZIM	ZIM	2.52%	$4.84M	$3.35B	41.68%	62 Neutral
ECO	Okeanis Eco Tankers Corp.	2.42%	$4.65M	$1.67B	46.35%	78 Outperform
WULF	TeraWulf Inc	2.36%	$4.54M	$6.77B	225.85%	50 Neutral
VTRS	Viatris	2.35%	$4.53M	$18.13B	46.84%	60 Neutral
HLF	Herbalife	2.35%	$4.51M	$1.65B	194.31%	71 Outperform
AU	Anglogold Ashanti PLC	2.33%	$4.48M	$53.60B	248.95%	73 Outperform

CPAI Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

42.22

Positive

100DMA

40.61

Positive

200DMA

38.20

Positive

Market Momentum

MACD

0.14

Positive

RSI

55.30

Neutral

STOCH

70.65

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CPAI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 43.48, equal to the 50-day MA of 42.22, and equal to the 200-day MA of 38.20, indicating a bullish trend. The MACD of 0.14 indicates Positive momentum. The RSI at 55.30 is Neutral, neither overbought nor oversold. The STOCH value of 70.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CPAI.

CPAI Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
CPAI	―	―	$189.37M	0.75%	―
SYLD	―	―	$930.62M	0.59%	―
PLDR	―	―	$813.93M	0.59%	―
ABFL	―	―	$794.64M	0.49%	―
BGDV	―	―	$757.07M	0.45%	―
XCHG	―	―	$658.62M	0.50%	―

Performance Comparison

CPAI

Counterpoint Quantitative Equity ETF

43.68

8.44

23.95%

SYLD

Cambria Shareholder Yield ETF

―

PLDR

Putnam Sustainable Leaders ETF

―

ABFL

Fcf Us Quality Etf

―

BGDV

Bahl & Gaynor Dividend ETF

―

XCHG

AB US Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents